(Q43554149)

English

Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

author name string

G J Yuen

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Y Lou

2

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

N F Thompson

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

V R Otto

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

T L Allsup

5

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

W B Mahony

6

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

H W Hutman

7

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

publication date

1 March 2001

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

41

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

277-288

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption.

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal.

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

How Many Pills Do Patients With HIV Infection Take?

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

Comparative pharmacokinetics of zidovudine (AZT) and its metabolite (G.AZT) in healthy subjects and HIV seropositive patients

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

The pharmacokinetics of lamivudine in patients with impaired hepatic function

1 reference

https://api.crossref.org/works/10.1177%2F00912700122010096

21 January 2018

Identifiers

10.1177/00912700122010096

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43554149&oldid=2100732552"